Mestinon (Pyridostigmine Bromide)

Pyridostigmine is a reversible acetylcholinesterase inhibitor. It blocks the enzyme that degrades acetylcholine, thereby raising the concentration of this neurotransmitter at the neuromuscular junction. The increased acetylcholine enhances stimulation of nicotinic receptors, leading to stronger muscle contractions.

The dosage of Mestinon is individualized. A qualified prescriber determines the appropriate amount based on the patient’s clinical condition, severity of symptoms, renal function, and response to therapy. Patients should follow the prescribing physician’s instructions and not adjust the dose on their own.

Safety data for pyridostigmine in pregnancy and lactation are limited. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing women. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss their situation with a qualified clinician.

To place an order, submit an enquiry on the Mestinon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mestinon (pyridostigmine) is longer‑acting and generally better tolerated than neostigmine, another acetylcholinesterase inhibitor. Pyridoxine has a slower onset but provides more sustained symptom control, making it the preferred oral agent for chronic management of myasthenia gravis, whereas neostigmine is often used for short‑term or intra‑operative purposes.

Mestinon should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use. Do not store in a refrigerator or freezer unless the manufacturer specifies otherwise.

Mestinon is taken orally, usually with a full glass of water. It can be administered with or without food, but consistent timing relative to meals helps maintain stable blood levels. Patients should swallow tablets whole and avoid crushing or chewing unless directed by a healthcare professional.

The most critical adverse events include severe cholinergic crisis, which can cause profound muscle weakness, respiratory failure, and paralysis, and bradycardia, which may lead to fainting or cardiac complications. Prompt medical attention is required if patients experience sudden worsening of weakness, difficulty breathing, or a markedly slow heart rate.

Mestinon is contraindicated in individuals with known hypersensitivity to pyridostigmine or any component of the formulation. It should also be avoided in patients with severe cardiac conduction disorders, such as untreated bradyarrhythmias, and in those taking high‑dose anticholinergic medications that could neutralize its effect.